Fewer trials.
Better chosen.
You cannot run a trial everywhere. SoilFlux tells you where a candidate should establish and persist, how far a result should carry to the next crop or market, and where the register is already crowded — before the budget is committed.
Site
Iowa, USA
42.0° N · −93.6° W
Organism
Bacillus spp.
genus-level · 1×10⁸ CFU/mL
Horizon
84 days
climatology-anchored
Inoculant trajectory
CFU/g · log scaleEstablishment
86%
Persistence · 90 d
61%
Confidence
Medium
Illustrative scenario output — establishment and persistence for a genus-level candidate at one site, with the confidence stated. Not a validated forecast.
Three questions, one evidence chain.
Which trials are worth running
Detecting a 10% yield difference in the field can take between 9 and 28 replicates. Nobody has that budget for every site. We rank candidate strains against candidate sites by where they should establish and persist — so the trials you do run are the ones that can actually settle the question.
Source · O'Callaghan et al. (2022), Soil Use and Management 38:1340–1369
Whether the result carries
A result in one crop, in one country, is a result in one crop, in one country. We score how comparable a new environment is — climate and soil, separately — and say how far the strain's behaviour should transfer, together with the minimal trial that would confirm it.
Transferability is not efficacy. We say so on every answer.
Where the register is already crowded
Being the eleventh product registered against the same target in the same country is a capital-allocation mistake that only shows up years later. We help you frame where a register is dense and where it is sparse, so market sequencing becomes a decision rather than an assumption.
Strongest today in the EU, at active-substance level. Every answer states where our coverage ends.
Illustrative comparability read — how close a new site is to a validated one, factor by factor, and which factor is doing the limiting.
Overall suitability
0.42
harmonic mean · Liebig's law
Limiting factor
soil pH
target range 5.8–6.8 · raise pH by ~1.0
pH
5.0
limitingOrganic C
1.5 %
lowTemperature
16°C avg
okRainfall
720 mm/yr
okTexture
Sandy loam
okSalinity (EC)
0.8 dS/m
ok
An answer you can hand to someone else.
The output is not an internal read-out. It is the thing you put in front of a distributor, a registrar, or your own management — every claim carrying its evidence, its confidence, and the boundary of what it does not cover.
Which is why exportability and defensibility are product requirements here, not polish. If it cannot survive being forwarded without you in the room, it is not finished.
What we will not claim.
This category has a trust problem, and it was earned. The fastest way for us to be useful is to be exact about where our answer stops.
Genus, not strain
Public data resolves to genus. Bacillus subtilis, thuringiensis and amyloliquefaciens are three different products under one name, and we cannot yet tell them apart. Strain-level resolution comes from your data, not ours.
Transferability, not efficacy
We predict establishment, persistence and comparability. We do not promise that a product works. Efficacy is the long-term goal, earned one controlled stage at a time — never asserted.
Coverage has edges
Regional validation is real in some places and thin in others, and register coverage is deeper inside the EU than outside it. Every answer says which it is.
Commercials last.
The order matters more than the price. Success criteria are agreed before any contract, so a result cannot be talked into being a win after the fact.
- 01A data-sharing agreement. No money changes hands.
- 02Your historical trial data, in whatever shape it is in.
- 03We agree, in writing, what would count as success — and what would count as failure.
- 04We deliver against it. Then, and only then, we talk commercially.
Co-development pilots are €0–40k fixed, and free where the data itself is the exchange.
Bring us your hardest transfer question.
The best first conversation is a real one — a candidate strain you are unsure about, a market you have been asked to enter, a trial programme you cannot afford to repeat.